Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital Stack, IsoDDE Engine, And Novartis/Lilly/J&J Partnerships Mean For Drug Discovery
Quick Links: Knowledge Base, Podcast, and Social
Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech
Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episodes on the Substack Podcast page.
For paid subscribers — your subscription unlocks the entire research archive (538+ deep-dives), every paid podcast episode, and full search inside the Knowledge Base. To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
For free subscribers — free posts and free podcast episodes are always public on Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.
Follow on Social — X · YouTube · TikTok · Instagram
Video Preview
🎧 Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Abstract
Iso closed a $2.1B Series B on May 12, 2026, led by Thrive Capital, the second consecutive lead by Thrive after the ~$600M Series A in April 2024
Cumulative disclosed equity now ~$2.7B, putting Iso in the same capital tier as Insitro and Recursion combined
Existing investors Alphabet and GV returned; new names include MGX (Abu Dhabi), Temasek (Singapore), CapitalG (Alphabet late-stage), and the UK Sovereign AI Fund
Reported post-money valuation in the $15-20B range, roughly 5-10x the next-largest AI-bio comparable by market value
Underwriting unit is IsoDDE, the unified drug design engine, descended from the AlphaFold 2 / AlphaFold 3 lineage built between DeepMind and Iso
Disclosed pharma partnerships: Novartis ($37.5M upfront, ~$1.2B in biobucks, 3 targets, signed Jan 2024), Eli Lilly ($45M upfront, ~$1.7B in biobucks, signed Jan 2024), J&J (terms not fully disclosed, more recent)
Headcount ~500 split across London HQ, Cambridge MA, and Lausanne; estimated annual burn $300-500M; runway roughly 4-6 years before next funding event
No Iso candidate has yet read out human Phase 2 data; entire valuation is platform thesis
Notable structural choice: zero pharma corporate venture equity on the round, preserving M&A optionality
UK Sovereign AI Fund participation is industrial policy expressed through cap table mechanics, with downstream implications for inbound investment screening and acquirer eligibility
Table of Content
The headline numbers and why two-point-one billion is not quite as wild as it sounds
The cap table breakdown, Thrive doubling down, and the sovereign money joining the party
What IsoDDE actually does once you get past the marketing
The pharma partnership math with Novartis, Lilly, and J&J
How Iso stacks up against Recursion, Schrödinger, Insitro, and the broader AI-bio cohort
The solve all disease pitch and why blue chip investors keep buying it
Burn rate, runway, and the IPO question that nobody on the cap table wants to answer yet
Strategic implications for pharma, biotech investors, and the rest of the stack
The headline numbers and why two-point-one billion is not quite as wild as it sounds
On May 12, 2026, Isomorphic Labs announced a $2.1B Series B led by Thrive Capital. For context, the prior round was around $600M in April 2024, also led by Thrive. That makes the Thrive check-writing pattern here look less like traditional venture and more like a growth equity continuation, with the lead doubling down at a meaningful markup to their prior basis. The total disclosed equity raised by the company is now approximately $2.7B, which puts Iso in the same neighborhood as Insitro and Recursion in cumulative capital and substantially ahead of Schrödinger on equity raised, though Schrödinger is publicly traded and has different optics around its capital structure.
The post-money valuation was not disclosed in the press materials, which is standard for private rounds but worth flagging. Industry chatter and partial reporting put it somewhere in a $15-20B range. At $2.1B raised against even a generous $20B post, the round implies a roughly 10% dilution event. That is reasonable for a Series B in percentage terms and absolutely enormous in absolute dollar terms for an AI-bio platform that has not publicly filed an IND off its internal pipeline yet. For outside underwriters trying to make sense of the price, the relevant comparable is not biotech Series B activity but rather frontier model lab fundraising. Anthropic, OpenAI, and xAI rounds are the closest analog by absolute dollars, structure, and investor mix. Iso is being underwritten less like a drug company and more like a foundation model company that happens to live in pharma. The math of that distinction matters when later thinking about runway and exit.
A check this size at this stage says a few things. The first is that capital intensity in AI-bio has decoupled from the rest of biotech. A traditional Series B in biotech five years ago would have been $80-200M, with maybe one or two outliers pulling $400M, like Verily or Grail in their day. Anything past that was strategic and structured. A $2.1B straight equity round in a private biotech, even a heavily AI-flavored one, would have been unthinkable in 2020. It is now the price of admission to be in the conversation.
The second is that the venture community has settled on a thesis that the marginal value of compute and senior research talent applied to AI-driven drug design is high enough to justify burn that would have looked reckless three years ago. Whether the thesis turns out to be right is a separate conversation. The round itself is a market signal that heat in the space has not cooled, even after the rough trajectory of Exscientia, the SPAC-era unwind of BenevolentAI, and the partial deflation of some of the earlier AI-bio darlings.
The third thing the round tells you is that Demis Hassabis is no longer the most expensive name in biotech that has yet to ship an approved drug. He is now a category. The Hassabis trade is a market, and this round sets the price.
The cap table breakdown, Thrive doubling down, and the sovereign money joining the party
